Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes: A Real-World Effectiveness Analyses in a National US Cohort of US Military Veterans with Inflammatory Bowel Disease

被引：0
|
作者：
Hou, J. K. [1 ]
Pham, C. [2 ]
Sansgiry, S. [3 ]
Modi, V. [2 ]
Waljee, A. K. [4 ]
机构：
[1] Baylor Coll Med, Sect Gastroenterol, 5207 Contour Pl, Houston, TX USA
[2] Baylor Coll Med, Med, Houston, TX USA
[3] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Med, Houston, TX USA
[4] Ann Arbor VA Univ Michigan, Med, Ann Arbor, VA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P750
引用
收藏
页码：880 / 881
页数：2
相关论文
共 50 条
  • [31] CLINICAL EFFICACY AND DURABILITY OF SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER SWITCHING FROM INTRAVENOUS INFLIXIMAB: A REAL-WORLD MULTICENTER PROSPECTIVE COHORT STUDY IN KOREA
    Kim, Kyuwon
    Hong, Sung Noh
    Kang, Sang-Bum
    Lee, Kang-Moon
    Koo, Ja Seol
    Jung, Yunho
    Lee, Beom Jae
    Yoon, Hyuk
    Kim, Hyung Wook
    Lim, Yun Jeong
    Lee, Hyun Seok
    Lee, Yoo Jin
    Lee, Jun
    Lee, Chang Kyun
    Moon, Jung Min
    Shin, Seung Yong
    Seo, Jeongkuk
    Choi, Chang Hwan
    GASTROENTEROLOGY, 2024, 166 (05) : S1136 - S1136
  • [32] Impact of Diagnostic Delay and Associated Factors on Clinical Outcomes in a US Inflammatory Bowel Disease Cohort
    Nguyen, Vu Q.
    Jiang, Dingfeng
    Hoffman, Sharon N.
    Guntaka, Srikar
    Mays, Jessica L.
    Wang, Anthony
    Gomes, Joseph
    Sorrentino, Dario
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (10) : 1825 - 1831
  • [33] Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in US Adults
    Wang, Tiansheng
    Yang, Jeff Y.
    Buse, John B.
    Pate, Virginia
    Tang, Huilin
    Barnes, Edward L.
    Sandler, Robert S.
    Sturmer, Til
    DIABETES CARE, 2019, 42 (11) : 2065 - 2074
  • [34] Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study
    Cristina Vergara-Dangond
    Marina Sáez Belló
    Mónica Climente Martí
    Pilar Llopis Salvia
    Juan José Alegre-Sancho
    Drugs in R&D, 2017, 17 : 481 - 485
  • [35] Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study
    Vergara-Dangond, Cristina
    Saez Bello, Marina
    Climente Marti, Monica
    Llopis Salvia, Pilar
    Jose Alegre-Sancho, Juan
    DRUGS IN R&D, 2017, 17 (03) : 481 - 485
  • [36] Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort
    Azzam, Nahla
    Aljebreen, Abdulrahman
    Alharbi, Othman
    Charabaty, Aline
    Alanazi, Mohammed
    Alkuwaykibi, Nashmi
    Alfaraidi, Jowaher
    Bashamil, Ahmad
    Almansour, Tarik
    Almadi, Majid
    ARAB JOURNAL OF GASTROENTEROLOGY, 2021, 22 (01) : 66 - 72
  • [37] Stable pharmacokinetics and biochemical markers of inflammatory bowel disease activity: Results from a real-world adalimumab biosimilar switching program
    Moore, A. C.
    Russell, D.
    Dart, R.
    Dias, S.
    Ghuman, S.
    Petri, B.
    Sharma, E.
    Ray, S.
    Anderson, S.
    Mawdsley, J.
    Irving, P. M.
    Samaan, M. A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I401 - I402
  • [38] Stable pharmacokinetics and biochemical markers of inflammatory bowel disease activity: Results from a real-world adalimumab biosimilar switching program
    Moore, A. C.
    Russell, D.
    Dart, R.
    Dias, S.
    Ghuman, S.
    Petri, B.
    Sharma, E.
    Ray, S.
    Anderson, S.
    Mawdsley, J.
    Irving, P. M.
    Samaan, M. A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I401 - I402
  • [39] ADVERSE ANTEPARTUM OUTCOMES IN PREGNANT WOMEN WITH INFLAMMATORY BOWEL DISEASE: A US POPULATION-BASED COHORT STUDY
    Dalal, Rahul S.
    Saxena, Akriti P.
    Lewis, James D.
    Lichtenstein, Gary R.
    GASTROENTEROLOGY, 2019, 156 (06) : S425 - S426
  • [40] Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)
    Abraham, Bincy
    Eksteen, Bertus
    Nedd, Khan
    Kale, Hrishikesh
    Patel, Dipen
    Stephens, Jennifer
    Shelbaya, Ahmed
    Chambers, Richard
    Soonasra, Arif
    ADVANCES IN THERAPY, 2022, 39 (05) : 2109 - 2127
12345